A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma

SRC: A Century of Science Brought to the Clinic

(2015) Alexey Aleshin et al.   NEOPLASIA

Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells

(2013) Alex Y Chang et al.   BMC CANCER

Src Family Kinases as Novel Therapeutic Targets to Treat Breast Cancer Brain Metastases

(2013) S. Zhang et al.   CANCER RESEARCH

Crosstalk between Activated and Inactivated c-Src in Hepatocellular Carcinoma

(2013) Mei-Lin Chen et al.   DISEASE MARKERS

Vitexicarpin Acts as a Novel Angiogenesis Inhibitor and Its Target Network

(2013) Bo Zhang et al.   Evidence-based Complementary and Alternative Medicine

Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell linesin vitro

(2013) Richard S. Finn et al.   HEPATOLOGY

Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells

(2012) María Pilar Sánchez-Bailón et al.   CELLULAR SIGNALLING

EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib

(2012) Zakaria Ezzoukhry et al.   INTERNATIONAL JOURNAL OF CANCER

SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo

(2012) Y. Pan et al.   MOLECULAR CANCER THERAPEUTICS

A Novel Monoclonal Antibody to Fibroblast Growth Factor 2 Effectively Inhibits Growth of Hepatocellular Carcinoma Xenografts

(2012) L. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Multi-Target Drugs: The Trend of Drug Research and Development

(2012) Jin-Jian Lu et al.   PLoS One

SKLB610: A Novel Potential Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibits Angiogenesis and Tumor Growth in Vivo

(2011) Zhi-Xing Cao et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth In Vivo

(2011) S. Zhang et al.   CLINICAL CANCER RESEARCH

Management of hepatocellular carcinoma: An update

(2011) Jordi Bruix et al.   HEPATOLOGY

Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma

(2011) Satoshi Shimizu et al.   INTERNATIONAL JOURNAL OF CANCER

Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells

(2011) K.-F. Chen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Identification of phosphorylase kinase as a novel therapeutic target through high-throughput screening for anti-angiogenesis compounds in zebrafish

(2011) S Camus et al.   ONCOGENE

Current Status of Src Inhibitors in Solid Tumor Malignancies

(2011) L. N. Puls et al.   ONCOLOGIST

Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors

(2010) John Araujo et al.   CANCER TREATMENT REVIEWS

Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?

(2010) R. S. Finn   CLINICAL CANCER RESEARCH

Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo

(2010) Gang Wei et al.   INTERNATIONAL JOURNAL OF CANCER

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

(2009) R Kumar et al.   BRITISH JOURNAL OF CANCER

Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals

(2009) Xiang H.-F. Zhang et al.   CANCER CELL

Src kinases as therapeutic targets for cancer

(2009) Lori C. Kim et al.   Nature Reviews Clinical Oncology

Expression of Src and FAK in Hepatocellular Carcinoma and the Effect of Src Inhibitors on Hepatocellular Carcinoma In Vitro

(2008) Grace M. Lau et al.   DIGESTIVE DISEASES AND SCIENCES